Jacobsen Villads, Pan Vladimir A, Tran Linh T, Vohradsky James, Bønnelykke Jonas, Schmidt Herø Cecilie, Johansen Jacob G, Tobias Frederiksen Anders, Singers Sørensen Brita, Busk Morten, Sauerwein Wolfgang A G, Rosenfeld Anatoly B, Bassler Niels
Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.
Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.
Phys Med Biol. 2025 Feb 18;70(5). doi: 10.1088/1361-6560/adb199.
The clinical advantage of proton therapy, compared to other types of irradiations, lies in its reduced dose to normal tissue. Still, proton therapy faces challenges of normal tissue toxicity and radioresistant tumors. To combat these challenges, proton boron capture therapy (PBCT) and neutron capture enhanced particle therapy (NCEPT) were proposed to introduce high-LET radiation in the target volume.. In this work, we performedexperiments with a V79 cell line to validate PBCT and introduced a novel approach to use NCEPT in proton therapy. We quantified the effectiveness of PBCT and NCEPT with microdosimetric measurements, Monte-Carlo simulations and microdosimetric kinetic RBE model (MKM).. No RBE increase was observed for PBCT. With the use of a tungsten spallation source, enough neutrons were generated in the incoming proton beam to measure significant neutron capture in the microdosimeter. However, no significant increase of RBE was detected when conventionalprotocol was followed. The resulting cell deactivation based RBE for NCEPT was found to be heavily dependent on which criteria was used to determine surviving colonies.. PBCT and NCEPT are two proposed treatment modalities that may have the potential to expand the cases in which proton therapy can be beneficial. Understanding the scope of these treatment methods and developing measurement protocols to evaluate and understand their RBE impact are the first step to quantify their potential in clinical context.
与其他类型的放疗相比，质子治疗的临床优势在于其对正常组织的剂量降低。然而，质子治疗仍面临正常组织毒性和抗辐射肿瘤的挑战。为应对这些挑战，人们提出了质子硼俘获疗法（PBCT）和中子俘获增强粒子疗法（NCEPT），以便在靶区内引入高传能线密度辐射。在这项工作中，我们用V79细胞系进行了实验，以验证PBCT，并引入了一种在质子治疗中使用NCEPT的新方法。我们通过微剂量测量、蒙特卡罗模拟和微剂量动力学相对生物效应模型（MKM）对PBCT和NCEPT的有效性进行了量化。PBCT未观察到相对生物效应增加。使用钨散裂源时，在入射质子束中产生了足够的中子，从而在微剂量计中测量到显著的中子俘获。然而，遵循传统方案时未检测到相对生物效应的显著增加。发现基于细胞失活的NCEPT相对生物效应严重依赖于用于确定存活集落的标准。PBCT和NCEPT是两种提出的治疗方式，可能有潜力扩大质子治疗有益的病例范围。了解这些治疗方法的范围并制定测量方案以评估和理解它们对相对生物效应的影响，是在临床环境中量化其潜力的第一步。
